Moleac

Executive Summary

Moleac is a Singapore-based biopharmaceutical company dedicated to developing innovative natural-product oral therapies for central nervous system (CNS) injuries and neurodegenerative disorders. Its flagship product, NeuroAiD (MLC901), is an evidence-based herbal formulation approved for post-stroke and traumatic brain injury recovery. NeuroAiD is currently marketed in over 30 countries, reflecting strong commercial traction and a well-established distribution network. The company’s science-driven platform leverages rigorous clinical evidence to support the efficacy and safety of its lead product, positioning it as a trusted therapy in neurorehabilitation. Building on the success of NeuroAiD, Moleac is actively expanding its pipeline into new indications, including spinal cord injury and Alzheimer’s disease. These efforts aim to address significant unmet medical needs in CNS disorders, where effective treatment options remain limited. With a robust R&D strategy and a growing body of clinical data, Moleac is poised to extend its leadership in neurotherapeutics. The company’s proven ability to commercialize in diverse markets and its focus on high-impact CNS indications underscore its potential for sustained growth and value creation.

Upcoming Catalysts (preview)

• H2 2026Phase 2/3 spinal cord injury efficacy data55% success
• 2027Alzheimer's disease Phase 2b trial initiation45% success
• 2028US FDA Investigational New Drug (IND) application for NeuroAiD30% success